Genmab

News

NICE changes stance on Genmab's cervical cancer drug

After saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart.

News

NICE says no to Genmab cervical cancer therapy

Genmab's recently approved therapy for relapsed cervical cancer has been turned down for NHS use in initial NICE guidance.

News

Genmab ends lung cancer drug development

Genmab has decided to stop development of a drug for cancer, acasunlimab for non-small cell lung cancer, following a review of its pipeline.

News

Representation on cellular level of lymphoma

Approvals extend use of Roche, AbbVie drugs in lymphoma

Patients in the US and EU with follicular lymphoma have new treatment options, thanks to new approvals for CD20xCD3 bispecifics Lunsumio and Epkinly.

News

Genmab agrees $8bn takeover of cancer biotech Merus

Genmab continues its shift from out-licensing drugs to developing its own drugs with an $8bn deal to buy Merus and its head and neck cancer therapy.

News

US District Court for the Western District of Washington at Seattle

AbbVie sues Genmab, claiming trade secrets theft

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets.

NICE changes stance on Genmab's cervical cancer drug

NICE says no to Genmab cervical cancer therapy

Genmab ends lung cancer drug development

Approvals extend use of Roche, AbbVie drugs in lymphoma

Genmab agrees $8bn takeover of cancer biotech Merus

AbbVie sues Genmab, claiming trade secrets theft

ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...

Discover a new era of healthcare panel engagement: Grounded ...

Genmab

Editor's Picks